Susan L Cohn Selected Research

ABT751

6/2014	Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
9/2010	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.
1/2010	Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.
2/2008	A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
8/2006	A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susan L Cohn Research Topics

Disease

97	Neuroblastoma 12/2022 - 01/2002
65	Neoplasms (Cancer) 01/2021 - 07/2003
4	Hypersensitivity (Allergy) 12/2022 - 09/2010
4	Neoplasm Metastasis (Metastasis) 01/2021 - 11/2008
3	Hypotension (Low Blood Pressure) 12/2022 - 11/2010
3	Chromosome Aberrations (Chromosome Abnormalities) 10/2021 - 10/2014
3	Hypoxia (Hypoxemia) 11/2016 - 11/2010
3	Ganglioneuroma 03/2013 - 12/2004
2	Neurologic Manifestations (Neurological Manifestations) 01/2020 - 12/2015
2	Residual Neoplasm 01/2019 - 09/2013
2	Opsoclonus-Myoclonus Syndrome (Kinsbourne Syndrome) 01/2018 - 03/2008
2	Ganglioneuroblastoma 03/2013 - 10/2009
2	Pain (Aches) 11/2010 - 09/2010
1	Fever (Fevers) 12/2022
1	Disease Progression 01/2021
1	Hypertrophy 01/2021
1	Microsatellite Instability 01/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2020
1	Lymphoma (Lymphomas) 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Hepatomegaly 10/2019
1	Thymus Hyperplasia 01/2017
1	Hypocalcemia 01/2016
1	Bacteremia 01/2016
1	Ataxia (Dyssynergia) 12/2015

Drug/Important Bio-Agent (IBA)

17	Biological ProductsIBA 12/2019 - 07/2004
10	3-Iodobenzylguanidine (Iobenguane)IBA 12/2021 - 10/2004
9	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 09/2005
8	Biomarkers (Surrogate Marker)IBA 10/2021 - 11/2005
6	dinutuximabIBA 12/2022 - 09/2010
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2010
5	Interleukin-2 (IL2)IBA 12/2022 - 09/2010
5	Monoclonal AntibodiesIBA 05/2017 - 09/2010
5	ABT751IBA 06/2014 - 08/2006
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 09/2010
4	Irinotecan (Camptosar)FDA LinkGeneric 11/2021 - 04/2005
4	N-Myc Proto-Oncogene ProteinIBA 01/2021 - 03/2013
4	Angiogenesis InhibitorsIBA 06/2007 - 10/2003
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 11/2008
3	Ferritins (Ferritin)IBA 01/2020 - 10/2014
3	5-hydroxymethylcytosineIBA 01/2020 - 11/2016
3	Phosphotransferases (Kinase)IBA 01/2019 - 10/2012
3	Isotretinoin (Accutane)FDA LinkGeneric 01/2018 - 09/2010
3	Indicators and Reagents (Reagents)IBA 04/2013 - 04/2005
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2011 - 12/2005
3	Pharmaceutical PreparationsIBA 08/2011 - 04/2006
3	multidrug resistance-associated protein 1IBA 04/2006 - 01/2004
2	Vorinostat FDA Link 11/2021 - 06/2015
2	Biological FactorsIBA 01/2021 - 01/2003
2	CytokinesIBA 01/2021 - 06/2013
2	Intravenous Immunoglobulins (IVIG)FDA Link 01/2020 - 01/2018
2	RNA (Ribonucleic Acid)IBA 01/2019 - 05/2014
2	Temozolomide (Temodar)FDA LinkGeneric 12/2018 - 01/2011
2	ChromatinIBA 11/2016 - 05/2012
2	Cysteine (L-Cysteine)FDA Link 11/2016 - 06/2010
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 09/2012 - 04/2007
2	Topotecan (Hycamtin)FDA LinkGeneric 11/2011 - 08/2010
2	Peptides (Polypeptides)IBA 06/2010 - 02/2007
2	FollistatinIBA 06/2010 - 10/2004
2	Tubulin ModulatorsIBA 02/2008 - 08/2006
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 02/2007 - 07/2003
2	CollagenIBA 01/2006 - 07/2004
2	Thrombospondin 1IBA 12/2004 - 10/2003
2	Messenger RNA (mRNA)IBA 10/2003 - 01/2002
1	Vincristine (Oncovin)FDA LinkGeneric 11/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	pembrolizumabIBA 01/2020
1	Cell-Free Nucleic AcidsIBA 01/2020
1	OTS167IBA 01/2019
1	TabletsIBA 12/2018
1	MLN 8237IBA 12/2018
1	Prednisone (Sone)FDA LinkGeneric 01/2018
1	LigandsIBA 01/2018
1	Iodine-123IBA 08/2017
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2017
1	Codon (Codons)IBA 12/2016
1	Insulin ReceptorIBA 12/2016
1	Anaplastic Lymphoma KinaseIBA 12/2016
1	LipidsIBA 11/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 11/2016
1	AlbuminsIBA 11/2016
1	ParaffinIBA 06/2016
1	Formaldehyde (Formol)FDA Link 06/2016
1	Alanine Transaminase (SGPT)IBA 01/2016
1	Melphalan (Alkeran)FDA LinkGeneric 01/2016
1	Buthionine SulfoximineIBA 01/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2016

Therapy/Procedure

39	Therapeutics 12/2022 - 05/2002
16	Drug Therapy (Chemotherapy) 12/2021 - 05/2002
10	Immunotherapy 12/2022 - 09/2010
7	Stem Cell Transplantation 01/2022 - 09/2010
4	Induction Chemotherapy 12/2021 - 04/2013
4	Radiotherapy 01/2019 - 09/2013
4	Aftercare (After-Treatment) 02/2013 - 07/2004
2	Duration of Therapy 12/2019 - 09/2010
2	Chemoradiotherapy 09/2013 - 06/2013
1	Terminal Care (Care, Terminal) 10/2020
1	Hematopoietic Stem Cell Transplantation 01/2018
1	Investigational Therapies (Experimental Therapy) 01/2017
1	Continuity of Patient Care 11/2016